Looking at clinical outcomes, a recent meta-analysis has shown that in cancer patients, the use of SGLT2 inhibitors can also significantly reduce the risks of all-cause mortality, heart failure hospitalization, or clinically significant arrhythmias, demonstrating their established CV benefit in these patients as well [53]. The gene discussed is SLC5A2; the disease is cancer.